Bayer, Aronora in Preclinical Mfg. Pact

Bayer HealthCare and Aronora, Inc. have entered a strategic alliance to manufacture Aronora’s AB-022 compound for the treatment of cardiovascular diseases. As a tenant of the U.S. CoLaborator, Bayer’s life sciences incubator facility in San Francisco, Aronora, will partner with Bayer HealthCare’s Global Biologics Development group in Berkeley for the preclinical manufacture of AB-022. 
 
“We have established a close, trusted relationship with Bayer HealthCare,” said Andras Gruber, chief executive officer of Aronora.  “We are thrilled to extend our relationship with this agreement. The close proximity of Bayer’s research and manufacturing sites to the CoLaborator has made this partnership a natural fit for us. The in-depth drug discovery and manufacturing expertise at Bayer has been valuable for advancing our compound towards the clinic.”
 
“This partnership with Aronora highlights Bayer’s unique Bay Area footprint spanning from early stage research through development and manufacturing. We are proud to offer our partners access to Bayer’s experts across the entire drug development process,” said Chris Haskell, head of Bayer’s U.S. Science Hub. “Our partnering strategy is designed to be flexible, to meet the needs of our collaborators—including start-ups like Aronora. We are excited to advance this collaboration to share our manufacturing expertise and capabilities.”